Patents by Inventor Mustafa Guzel

Mustafa Guzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 10030011
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: July 24, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20180071297
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 15, 2018
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 9833457
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriatic arthritis.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: December 5, 2017
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20170252343
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriatic arthritis.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 7, 2017
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 9687489
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriasis.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: June 27, 2017
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20160296526
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to psoriasis.
    Type: Application
    Filed: June 16, 2016
    Publication date: October 13, 2016
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
    Patent number: 9393245
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: July 19, 2016
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20150374700
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Substituted azoanthracene derivatives and intermediates for preparation thereof
    Patent number: 9175003
    Abstract: The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 3, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, Jr., Jennifer L. R. Freeman, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Santhosh Kalpathy, Stephen Thomas Davis, Thomas Scott Yokum
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 9163022
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: October 20, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 9120813
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: September 1, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Santhosh Kalpathy, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof
    Publication number: 20150148539
    Abstract: The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 28, 2015
    Inventors: Adnan M.M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, JR., Jennifer L.R. Freeman, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Santhosh Kalpathy, Stephen Thomas Davis, Thomas Scott Yokum
  • Oxadiazoanthracene Compounds for the Treatment of Diabetes
    Publication number: 20150087640
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Santhosh Kalpathy, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 8987295
    Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: March 24, 2015
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, Jr., Jennifer L. R. Freeman, Kalpathy Santhosh, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 8933222
    Abstract: The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and methods of synthesizing precursors to these oxadiazoanthracene derivatives.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: January 13, 2015
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors
    Publication number: 20140371250
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Application
    Filed: September 4, 2014
    Publication date: December 18, 2014
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 8853226
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: October 7, 2014
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    Publication number: 20140200212
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 17, 2014
    Applicant: High Point Pharmaceuticals, LLC
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Oxadiazoanthracene Compounds for the Treatment of Diabetes
    Publication number: 20140187769
    Abstract: The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and methods of synthesizing precursors to these oxadiazoanthracene derivatives.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 3, 2014
    Applicant: TransTech Pharma, LLC
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Aryl carbonyl derivatives as therapeutic agents
    Patent number: RE45670
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 15, 2015
    Assignee: NOVO NORDISK A/S
    Inventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper F. Lau, Paw Bloch, Mustafa Guzel, Santhosh Chidambareswaran Kalpathy, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen, Jesper Lau